U.S., July 1 -- ClinicalTrials.gov registry received information related to the study (NCT07675070) titled 'Safety and Effectiveness Evaluation of Temozolomide (Amitzo, NanoAlvand) in Patients With Grade III and IV Glioma Tumors' on June 23.
Brief Summary: This is a phase IV, post-marketing, observational, cohort study for safety and effectiveness evaluation of Amitzo(R) in Iranian patients with grade III and IV glioma tumors. No control group is considered in the study design. The primary objective is to evaluate the incidence of hepatic injury in patients with grade III and IV glioma tumors, treated with Amitzo(R).
Study Start Date: March 22
Study Type: OBSERVATIONAL
Condition:
Brain Tumor
Grade III Glioma
Grade IV Glioma
Interventi...